

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

Use this check box to generate the required 483 statement on page 1 for medical device observations.

DISTRICT ADDRESS AND PHONE NUMBER

4040 North Central Expressway, Suite 300
 Dallas, TX 75204
 (214) 253-5200 Fax: (214) 253-5314
 ORAPharm2_responses@fda.hhs.gov

DATE(S) OF INSPECTION

11/18/2019-11/22/2019*

FEI NUMBER

3004102002

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED

Jack R. Munn, Owner/Pharmacist-in-Charge

FIRM NAME

MPRX, Inc. dba Medical Park Pharmacy

STREET ADDRESS

8230 Elmbrook Dr Ste 600B

CITY, STATE, ZIP CODE, COUNTRY

Dallas, TX 75247-4144

TYPE ESTABLISHMENT INSPECTED

Producer of Non-Sterile Drugs

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically, during my review of your October 2019 Formula Worksheets, (b) (4) of (b) (4) lots of products were produced using at least one expired bulk drug substance/chemical including, but not limited to the following: Phenylephrine, Desonide, Dexamethasone, Liothyronine, Acesulfame Potassium, Gabapentin and Cyclobenzaprine.

OBSERVATION 2

Calibration of mechanical equipment is not performed daily or on a routine schedule designed to assure proper performance.

Specifically,

- a) You have not calibrated the scale used to weigh bulk drug substances/chemicals since you moved to this location.
- b) You stated, and I observed you do not verify the weighing of ingredients/components for each lot made.
- c) Formula Worksheets do not list ingredients and the quantity of each in the order of the manufacturing process.

OBSERVATION 3

You produced highly potent drugs without providing adequate to prevent cross-contamination.

Specifically, you do not document the cleaning of the (b) (4) hood and the hood used and non-dedicated equipment (i.e. (b) (4), etc.) to demonstrate control of cross contamination between highly potent drugs.

SEE
REVERSE
OF THIS
PAGE

EMPLOYEE(S) SIGNATURE

Claire M. Minden

Digitally signed by Claire M. Minden -S
 DN: c=US, o=U.S. Government, ou=HHS,
 ou=FDA, ou=People,
 0.9.2342.19200300.100.1.1=1300178102,
 cn=Claire M. Minden -S
 Date: 2019.11.22 13:34:56 -06'00'

EMPLOYEE(S) NAME AND TITLE (Print or Type)

Claire M. Minden, Investigator

DATE ISSUED

11/22/2019

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG

DISTRICT OFFICE ADDRESS AND PHONE NUMBER
 4040 North Central Expressway, Suite 300
 Dallas, TX 75204
 (214)253-5200 Fax:(214)253-5314
 ORAPharm2_responses@fda.hhs.gov

DATE(S) OF INSPECTION
 11/18/2019-11/22/2019*

FEI NUMBER
 3004102002

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
 Jack R. Munn, Owner/Pharmacist-in-Charge

FIRM NAME
 MPRX, Inc. dba Medical Park Pharmacy

STREET ADDRESS
 8230 Elmbrook Dr Ste 600B

CITY, STATE, ZIP CODE, COUNTRY
 Dallas, TX 75247-4144

TYPE ESTABLISHMENT INSPECTED
 Producer of Non-Sterile Drugs

OBSERVATION 4

Vermin was observed in your production area.

Specifically, on November 20, 2019, I observed an insect in the pharmacy area on the floor where compounding activities occur.

***DATES OF INSPECTION**

11/18/2019(Mon), 11/19/2019(Tue), 11/20/2019(Wed), 11/22/2019(Fri)

<p align="center">SEE REVERSE OF THIS PAGE</p>	<p>EMPLOYEE(S) SIGNATURE</p> <p><i>Claire M. Minden</i></p> <p><small>Digitally signed by Claire M. Minden -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300178102, cn=Claire M. Minden -S Date: 2019.11.22 13:35:47 -06'00'</small></p>	<p>EMPLOYEE(S) NAME AND TITLE (<i>Print or Type</i>)</p> <p>Claire M. Minden, Investigator</p>	<p>DATE ISSUED</p> <p>11/22/2019</p>
--	---	--	--------------------------------------